- Home
- SAFE vs SNDX Comparison
SAFE vs SNDX Comparison
Compare SAFE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- SNDX
- Stock Information
- Founded
- SAFE 2016
- SNDX 2005
- Country
- SAFE United States
- SNDX United States
- Employees
- SAFE N/A
- SNDX N/A
- Industry
- SAFE Real Estate Investment Trusts
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- SNDX Health Care
- Exchange
- SAFE Nasdaq
- SNDX Nasdaq
- Market Cap
- SAFE 1.3B
- SNDX 1.2B
- IPO Year
- SAFE 2017
- SNDX 2016
- Fundamental
- Price
- SAFE $18.57
- SNDX $13.10
- Analyst Decision
- SAFE Buy
- SNDX Strong Buy
- Analyst Count
- SAFE 9
- SNDX 10
- Target Price
- SAFE $25.22
- SNDX $36.00
- AVG Volume (30 Days)
- SAFE 413.2K
- SNDX 2.2M
- Earning Date
- SAFE 05-05-2025
- SNDX 03-03-2025
- Dividend Yield
- SAFE 3.79%
- SNDX N/A
- EPS Growth
- SAFE N/A
- SNDX N/A
- EPS
- SAFE 1.48
- SNDX N/A
- Revenue
- SAFE $388,662,000.00
- SNDX $23,680,000.00
- Revenue This Year
- SAFE N/A
- SNDX $274.86
- Revenue Next Year
- SAFE $7.80
- SNDX $130.47
- P/E Ratio
- SAFE $12.60
- SNDX N/A
- Revenue Growth
- SAFE 3.15
- SNDX N/A
- 52 Week Low
- SAFE $15.55
- SNDX $12.06
- 52 Week High
- SAFE $28.80
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- SAFE 55.86
- SNDX 37.87
- Support Level
- SAFE $18.46
- SNDX $12.26
- Resistance Level
- SAFE $19.53
- SNDX $16.50
- Average True Range (ATR)
- SAFE 0.69
- SNDX 0.95
- MACD
- SAFE 0.08
- SNDX -0.29
- Stochastic Oscillator
- SAFE 67.24
- SNDX 19.56
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.